Natrixam

Quick links to important sections

Natrixam

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Natrixam

Quick Facts

Property Description
Active Ingredients Amlodipine, Indapamide
Form Film-coated tablet (Modified-release)
Pharmacological Class Dual-mechanism Antihypertensive Agent
Common Use Essential hypertension (high blood pressure)
Origin Synthetic

What is Natrixam and its Pharmacological Class?

Natrixam is a synthetic, fixed-dose combination product classified as a Dual-mechanism Antihypertensive Agent, designed for the management of essential hypertension. This medication is administered as an oral dosage form and combines two distinct pharmacological classes into a single tablet, offering a complementary approach to blood pressure control. This strategy of combining two agents is clinically recognized for achieving sustained antihypertensive effects. As a prescription-only medicine, its design focuses on providing a compound action to effectively manage persistent elevated blood pressure.

Composition and Drug Form (Amlodipine and Indapamide)

The drug's core composition relies on two separate active ingredients: Amlodipine and Indapamide. Amlodipine belongs to the pharmacological class of Calcium Channel Blockers (CCB), while Indapamide is a Thiazide-like Diuretic and a sulfonamide derivative.

The simultaneous use of both agents ensures a comprehensive reduction in blood pressure, a strategy that is a well-established method for managing high blood pressure. The medication is prepared as a specific film-coated tablet designed for modified release, a feature intended to ensure the consistent, simultaneous delivery of both agents over time.

General Purpose of the Dual-Action Formulation

The general purpose of this fixed-dose combination is to achieve a more powerful and sustained reduction in blood pressure than using either component alone. This is accomplished through two complementary physiological actions. Amlodipine promotes arterial relaxation (vasodilation), while Indapamide supports a modest diuretic activity by facilitating the gentle removal of excess salt and water. The combination is often proposed as substitution therapy for adults whose essential hypertension is already stable using the individual components, providing a simplified therapeutic regimen.

What side effects are possible with Natrixam?

Possible Side Effects and Safety Information

The official safety profile for Natrixam, a fixed-dose combination of Amlodipine and Indapamide, is structured by frequency classification and System-Organ-Class (SOC) grouping, as documented by regulatory authorities. The adverse reactions reported primarily reflect the established safety profiles of its two active components.


Frequency-Classified Adverse Reactions

Adverse events are categorized by how often they are observed in clinical use:

  • Common (may affect up to 1 in 10 people): Reactions include dizziness, headache, ankle swelling (oedema), tiredness, and hypokalaemia (low potassium in the blood).
  • Uncommon (may affect up to 1 in 100 people): Documented events include hypotension (low blood pressure).
  • Very Rare (may affect up to 1 in 10,000 people): Serious reactions in this category include angioedema (severe swelling of face or throat) and myocardial infarction.

Key Safety Constraints and Special Populations

Specific safety considerations are defined in regulatory labeling:

  • Time-Related Patterns: Events such as headache and dizziness are noted to be more common at the beginning of treatment.
  • Metabolism Monitoring: Due to the Indapamide component, the drug’s use requires the periodic determination of serum electrolytes, as potassium depletion (hypokalaemia) is a major risk.
  • Hepatic Impairment: Caution is explicitly advised for patients with severe hepatic impairment due to the risk of hepatic encephalopathy.
  • Grapefruit Interaction: Co-consumption with grapefruit or grapefruit juice is not recommended as it may increase exposure to Amlodipine.

Overdose and Emergency Response

Overdose and when to seek help

Documented Manifestations and Severe Outcomes

Official regulatory documentation on Natrixam overdose outlines risks stemming from its two components. Overdose is principally characterized by profound and prolonged hypotension (extremely low blood pressure), which may lead to shock or coma. Documented clinical signs also include bradycardia (slow heartbeat) or reflex tachycardia, as well as other signs of central nervous system and gastrointestinal distress.

Life-threatening outcomes cited in the official labeling involve the potential for severe arrhythmias, notably Torsades de pointes, which is primarily linked to severe hypokalaemia (low potassium) and hyponatraemia (low sodium) induced by the diuretic component. The fall in blood pressure may also lead to cerebral or myocardial ischaemia.


Regulator-Mandated Emergency Actions

Immediate actions must be taken when an overdose is suspected. The official guidance requires immediate medical attention for all massive overdose scenarios. Emergency services must be contacted immediately if collapse, seizures, or breathing difficulty are observed.

Management is symptomatic and supportive as no specific antidote is known. This necessitates continuous cardiac and respiratory monitoring. Furthermore, monitoring of serum electrolytes and renal function is essential. Official labeling notes that specific populations, including the elderly and patients with cirrhosis or existing cardiac conditions, are at higher risk for severe electrolyte disturbances in this context.

Therapeutic Uses of Natrixam

What Natrixam Treats: Main Uses and Benefits

This medication is relevant for easing the management of essential hypertension (chronic high blood pressure), which is a condition presenting with systemic imbalance. Its therapeutic role is applied in addressing the measurable, chronic elevation of arterial pressure. The key therapeutic applications include serving as substitution therapy for adults whose blood pressure is already stable on the individual components, amlodipine and indapamide, and may assist with supporting the long-term stability of the cardiovascular system.

The core benefit to the patient is considered relevant as it may assist with maintaining functional stability by combining two treatments into a single tablet.

Quick Fact: Relief for Essential Hypertension

Property Description
Primary Condition Essential hypertension (chronic high blood pressure)
Therapeutic Role Contributes to stable, long-term blood pressure management
Clinical Scenario Substitution therapy for regimen simplification
Patient Benefit May assist with supporting the overall long-term stability of the cardiovascular system

Regulatory References

  1. Health Products Regulatory Authority Summary of Product Characteristics

Eligibility and Restrictions for Use

Who Can and Cannot Use Natrixam?

This section outlines the official population eligibility and non-eligibility rules for Natrixam (Amlodipine/Indapamide) as stated in governmental regulatory documents. Use is primarily established for Adults (18 years and older) whose essential hypertension is already stable using the individual components, serving as substitution therapy.

Non-Eligible Populations (Contraindications)

Natrixam must not be used by patients with specific pre-existing conditions or physiological states. Contraindications include:

  • Severe Organ Dysfunction: Patients with severe renal failure (creatinine clearance below 30 mL/min) or severe hepatic impairment (including hepatic encephalopathy).
  • Electrolyte/Cardiovascular Instability: Those with hypokalaemia (low plasma potassium), severe hypotension, shock, or certain severe cardiac conditions (e.g., outflow tract obstruction, unstable heart failure after a heart attack).
  • Hypersensitivity: Known allergy to the active substances, other sulfonamide derivatives, or dihydropyridine derivatives.
  • Lactation: Women who are breastfeeding.

Age and Developmental Stage Restrictions

Population Group Eligibility Status
Children & Adolescents Not established; use is not recommended.
Pregnant Women Not recommended; a switch to alternative treatment is advised.
Older Adults Permitted, but treatment must be determined according to renal function.

What should I know about interactions with other medicines?

Natrixam, a combination of indapamide and amlodipine, carries interaction risks associated with both active substances. Certain combinations are contraindicated or not recommended due to the potential for serious adverse effects.

Contraindicated and Not Recommended Combinations

  • Dantrolene (infusion): This combination is contraindicated due to the risk of life-threatening interactions involving calcium metabolism and the heart.
  • Lithium: Use is not recommended as indapamide can decrease the excretion of lithium, significantly increasing plasma lithium levels and the risk of toxicity.
  • Grapefruit or Grapefruit Juice: Consumption should be avoided as it can increase the concentration of amlodipine in the blood, leading to an unpredictable increase in the blood pressure-lowering effect.

Interactions Requiring Precautions for Use

Close monitoring or dose adjustment is necessary when combining Natrixam with the following categories, typically due to effects on electrolytes or drug metabolism:

Interacting Product Category Key Mechanism / Risk Monitoring Requirement
Torsade de Pointes Inducing Medicines (e.g., specific anti-arrhythmics, antipsychotics) Increased risk of Torsade de Pointes due to indapamide-induced low potassium (hypokalaemia). Plasma potassium and ECG monitoring.
CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin) Increased exposure to amlodipine, raising the risk of severe low blood pressure. Clinical monitoring; dose adjustment may be required.
Simvastatin (high cholesterol medicine) Amlodipine may increase Simvastatin levels. Simvastatin dose must not exceed 20 mg daily.
ACE Inhibitors (e.g., ramipril, lisinopril) Risk of sudden low blood pressure and acute kidney failure, especially in pre-existing sodium-depleted patients. Hydration and renal function monitoring at the start of treatment.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Reduced antihypertensive effect and risk of acute kidney failure in dehydrated patients. Hydration and renal function monitoring.

It is essential to inform a healthcare professional of all medicines, supplements (especially St. John's Wort), and products being used, as indapamide's impact on electrolyte balance and amlodipine's metabolism can affect numerous other treatments.

Mechanism of Action

How Natrixam Works: The Mechanism of Action


Vascular Tone Modulation: Arterial Relaxation

One component of this combination acts directly on the muscle cells of peripheral arteries, functioning as a calcium channel inhibitor. By blocking the entry of calcium ions ( Ca^2+) through extbfL-Type Voltage-Dependent Calcium Channels, the drug interferes with the molecular signal required for muscle contraction. This core action causes vasodilation (widening of the vessels) and reduces the Total Peripheral Resistance to blood flow, which in turn results in a reduction of the pressure exerted on the artery walls.


Fluid and Electrolyte Regulation: Kidney Salt Excretion

The complementary component executes its mechanism in the kidney tubules by inhibiting the extbfSodium-Chloride Cotransporter (NCC). By interrupting the reabsorption of Na^+ and Cl^-, the drug promotes their increased excretion, accompanied by water. This physiological adjustment reduces the plasma volume—the total amount of fluid circulating in the bloodstream—thereby resulting in a volume-dependent decrease in circulatory pressure.


Combined Physiological Adjustment

The two components work synergistically to modulate the two main physical determinants of circulatory pressure: the volume of the fluid and the resistance of the vessels. By acting on two distinct regulatory systems, the drug achieves a combined physiological effect that leads to a reduction of force within the circulatory system.

Dosage and Administration Information

How to Use Natrixam

Natrixam is used according to a standardized administration protocol. It is available as a fixed-dose, modified-release film-coated tablet in strengths such as 1.5 mg Indapamide / 5 mg Amlodipine and 1.5 mg Indapamide / 10 mg Amlodipine. The medicine is administered exclusively via the oral route.


Dosing and Administration Schedule

The standard regimen involves taking one tablet daily, which is the maintenance dose for continuous therapy. This combination is generally intended as substitution therapy for adults whose blood pressure is already controlled by administering the individual components at the same fixed doses. The fixed-dose format means there is no initial titration phase for this specific product.

The frequency is once daily, and the tablet should preferably be taken in the morning. Maintaining a consistent same time each day schedule is part of the established usage pattern.


Procedural Instructions and Handling

The tablet must be swallowed whole with a glass of water. It is a procedural requirement that the tablet must not be crushed, chewed, or divided, due to its modified-release formulation, which ensures the controlled delivery of the drug over time. The administration is permitted with or without food.

Use for Specific Populations

Older adults do not require a specific dose adjustment. However, the medicine is not recommended for patients under 18 years of age due to insufficient data, nor is it recommended for patients with severe hepatic or renal impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Natrixam


Evidence for use as Substitution Therapy in Essential Hypertension

The research exploring the fixed-dose combination (Natrixam) primarily focused on simplifying the treatment regimen for patients whose high blood pressure is already well-monitored on the two separate components. Regulatory review relied on pharmacokinetic bioequivalence studies which examined how the body processed the fixed-dose tablet compared to the two separate tablets. The findings described a similar processing, which forms the rationale for substitution. However, dedicated, long-term randomized controlled trials (RCTs) have generally not been performed to directly compare the fixed combination against the loose combination for this substitution goal.


Evidence for use in Specific Hypertensive Scenarios

Beyond the substitution indication, research has explored the combination using observational study designs (real-world evidence) and secondary analyses of previous trials. Studies monitored patient groups with conditions like Isolated Systolic Hypertension (ISH) and those with coexisting medical conditions, such as Type 2 Diabetes. Outcomes research examined included blood pressure metrics and the proportion of participants reaching specific blood pressure targets, providing insight into short-term changes.


Research on Long-Term Outcomes and Treatment Persistence

The available evidence base was studied for limited follow-up durations, often up to one year, meaning that long-term outcomes are not well characterized. Research examined treatment adherence and persistence, with findings indicating a single tablet may help simplify the routine compared to taking multiple separate tablets. However, comparative evidence is lacking in terms of definitive, long-term cardiovascular stability between the two approaches.


Evidence in Special Populations

Research studies explored the use of this combination in specific groups, including older adults (aged 55 years) and patients with coexisting medical conditions. However, data for certain groups remain insufficient. Specifically, limited information is available for the fixed combination's use in children and adolescents, as well as in patients with severe issues related to kidney or liver function.


Study Gaps and Uncertainty

Despite the evidence supporting the substitution rationale, certainty remains low in several key areas. The primary limitation is the lack of dedicated, head-to-head randomized controlled trials (RCTs) specifically comparing the long-term effectiveness of the fixed combination versus the loose combination. The approval relies on the established data of the individual components. Subgroup findings are uncertain, and follow-up durations were limited in many studies.

Key Studies & References

  1. Health Products Regulatory Authority (HPRA) - Summary of Product Characteristics (Natrixam)
  2. A fixed combination of amlodipine and indapamide retard in the treatment of uncontrolled arterial hypertension in people over 55 (ARBALET Study Registry)

Frequently Asked Questions (FAQ)

Common questions about Natrixam (FAQ)


Q: Is Natrixam intended to be a long-term medication for chronic conditions?

Official documents describe this medicine as a maintenance dose for continuous therapy in adults with essential hypertension (high blood pressure). It is generally used as a substitution therapy for those whose blood pressure is already stable on the individual components. The established usage pattern suggests it is intended for the long-term management of this chronic condition.


Q: How quickly does Natrixam start to have an effect after beginning treatment?

The initial blood pressure reduction may start within 6 to 12 hours of the first dose. However, a steady state (consistent concentration) of the medicine in the blood takes about 7 to 10 days of daily use. Official documents describe that the full antihypertensive effect may require 1 to 2 weeks or longer to fully develop.


Q: Is it safe to consume alcohol while taking Natrixam?

Official information notes that alcohol consumption may need to be limited or avoided. This is because alcohol may worsen common side effects like headache and dizziness. Furthermore, it may enhance the orthostatic effect, increasing the risk of feeling dizzy or lightheaded when standing up too quickly.


Q: Does Natrixam have a known potential to cause weight changes?

Official safety information reports that unusual weight gain or loss and even rapid weight gain are possible side effects. These effects are classified as less common and are typically associated with the indapamide component of the medicine.


Q: What are the signs of low potassium or dehydration associated with Natrixam's diuretic component?

Because this medicine can affect electrolyte balance (salt levels) and fluid volume, official documents list signs to be aware of. These signs include muscle pains or cramps, unusual tiredness or weakness, dry mouth, increased thirst, dizziness, confusion, or fast/irregular heartbeat.


Q: What should be done if someone experiences ankle or foot swelling while on Natrixam?

Ankle or foot swelling (oedema) is listed in the official safety profile as a common side effect of this medicine. Regulatory guidance describes that a healthcare professional should be consulted if this or any other side effect becomes bothersome or severe.


Q: Does Natrixam affect blood sugar levels, especially for people with diabetes?

Yes, the indapamide component may cause changes, including an increase, in blood sugar levels (hyperglycemia). For this reason, official regulatory labeling indicates that patients with pre-existing high blood sugar or diabetes are a group for whom special monitoring may be necessary during treatment.


Q: Can Natrixam be used by people with a history of gout?

Gout is considered a pre-existing condition for which information in the official documentation suggests consultation with a healthcare professional. Official safety information indicates that the indapamide component may potentially increase the level of uric acid in the blood (hyperuricemia), which can be a factor in gout.


Q: Are there any reported effects of Natrixam on sleep or insomnia?

Official safety information includes reports of effects on sleep. Both trouble sleeping (insomnia) and drowsiness (feeling sleepy) are side effects associated with the active components of the medicine.


Q: Is a persistent cough a known or reported side effect of Natrixam?

Yes, a cough or hoarseness is a side effect that has been reported in association with the indapamide component. Regulatory guidance generally describes that any bothersome side effects should be reported to a healthcare professional.


Q: Are there special patient warnings for people with a history of lupus?

Yes, there is a specific official warning regarding Systemic Lupus Erythematosus (SLE). Regulatory documents indicate that the indapamide component may activate or worsen this condition.


Q: Why do some people experience muscle cramps when taking Natrixam?

Muscle cramps or spasms are listed in the safety profile as reported side effects. These physical symptoms are often related to the medicine's effect on electrolyte balance, specifically the risk of developing hypokalaemia (low potassium) due to the diuretic component.


Q: Can Natrixam impact sexual health or function?

Adverse effects on sexual health or function are reported in the official safety information. These include a decreased interest in sexual intercourse and, in males, the inability to have or keep an erection or a general loss of sexual ability or drive.


Q: Does Natrixam affect cholesterol levels or blood lipid profiles?

Official research concerning the indapamide component indicates that it is generally described as not interfering with lipid metabolism. This means that it is not expected to negatively affect levels of triglycerides, LDL-cholesterol, or HDL-cholesterol (often called 'good' and 'bad' cholesterol) in the blood.


Q: Are there any specific warnings about heat exposure while taking Natrixam?

While there is no specific warning label for 'heat exposure,' official guidance states that maintaining adequate hydration is important. This precaution is especially important in conditions that cause excess sweating, such as high heat or heavy exercise, as the diuretic component increases the risk of dehydration.


Q: Is it normal to experience more frequent urination when first taking Natrixam?

Yes, frequent urination is a reported effect, especially when starting treatment. This happens because the indapamide component acts as a diuretic, which works by increasing the urinary excretion of salt and water, thereby naturally increasing urine output. Official product information lists this as a less common side effect.


Q: Are there any specific warnings about the drug's effect on heart rate?

Official information lists a fast or irregular heartbeat (palpitations) as a less common side effect linked to one of the components. Severe cardiac conditions are also listed as contraindications where the medicine must not be used. However, the gradual onset of the amlodipine component's action means that an immediate change in heart rate is generally not noted after the dose.


Q: What is the official guidance on managing dehydration while on Natrixam?

Official guidance states that maintaining adequate hydration is important while taking this medicine. Consuming enough water is noted, especially when experiencing fluid loss, such as excess sweating, vomiting, or diarrhea. Dehydration can potentially lead to dizziness or lightheadedness due to low blood pressure.


Q: What is the risk classification for allergic reactions to Natrixam?

A known hypersensitivity (severe allergy) to any of the active substances or related chemical derivatives is listed as a contraindication, meaning the drug must not be used. A severe reaction, such as angioedema (swelling of the face, throat, or lips), is classified as a very rare side effect. Other reactions, like hives and skin rash, are reported as less common.

How should Natrixam be stored and disposed of?

How to Store and Dispose of Natrixam

Natrixam tablets must be stored according to regulatory requirements to ensure product stability and safety, as documented in official labeling.

Storage Requirements

Item Requirement
Temperature (Blisters) Store below 30 C
Temperature (Bottles) Requires no special storage conditions
Child Safety Keep out of the sight and reach of children
Stability Do not use after the expiry date

Disposal Instructions

To protect the environment, the medicine must not be thrown away via wastewater or household waste.

Patients are instructed to ask the pharmacist how to throw away medicines they no longer use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Natrixam found in:

A-Z Index: